Menyan (Ethinylestradiol, Norgestimate)

Ethinylestradiol activates estrogen receptors, while norgestimate is metabolised to active progestogenic compounds that bind progesterone receptors. Together they suppress the release of gonadotropins, preventing ovulation, thicken cervical mucus, and alter the endometrium to inhibit implantation.

The dosing regimen for Menyan is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule should follow the prescriber’s instructions.

Menyan is contraindicated during pregnancy because it is designed to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding; clinicians usually advise against use while nursing unless benefits outweigh potential risks.

To order Menyan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Menyan contains ethinyloestradiol and norgestimate, a progestogen with a relatively low androgenic profile. Compared with formulations using levonorgestrel or desogestrel, Menyan may offer a different balance of bleeding pattern control and side‑effect profile, but efficacy in preventing pregnancy is comparable across approved combined oral contraceptives.

Menyan tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Menyan is taken orally, usually once each day at the same time, with or without food. Patients should follow the prescribed cycle, typically 21 consecutive active tablets followed by a 7‑day hormone‑free interval, unless directed otherwise by their clinician.

Serious risks include venous thromboembolism, arterial thrombosis leading to stroke or myocardial infarction, severe hypertension, and rare liver tumors. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Menyan should not be used by women who are pregnant, have known thrombophilia, a history of estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or who are over 35 and smoke. Contraindications are listed in the product label and should be reviewed by a healthcare professional.